Inclusion Criteria

Inclusion criteria:

- Is scheduled for breast biopsy due to a suspicious mass palpable or ≥1 cm on
mammogram

- Must be able to receive two doses of study medication 7 days apart prior to surgery

- Has histologically confirmed invasive breast cancer with ER positive, ER and/or PR
negative histology or triple negative (for ER, PR, HER-2) histology

- Has an ECOG performance status ≤ 2

- Has no clinically significant laboratory or cardiac abnormalities

- Has a negative serum pregnancy test at Screening as is either post menopausal,
sterile or willing to use an approved method of contraception.

- Is able to swallow and retain oral medication

Exclusion criteria:

- Has a concomitant medical condition that precludes adequate study treatment
compliance or assessment, such as: a.
Bleeding disorders that would increase risks of additional core biopsy for biomarkers
b. Morbid obesity

- Is currently receiving treatment with a medication on the prohibited medication list

- Has allergy to benzamides or inactive components of study drug

- Is participating in another clinical trial or has received another investigational
agent within 30 days prior to informed consent